Education
About Us
Working with TipRanks
Follow Us
DiaSorin S.p.A. (IT:DIA)
:DIA
DIA Stock Chart & Stats
Day’s Range― - ―
52-Week Range€83.14 - €112.35
Previous CloseN/A
Volume135.55K
Average Volume (3M)176.04K
Market Cap
€4.67B
Enterprise Value€5.57B
Total Cash (Recent Filing)€0.00
Total Debt (Recent Filing)€672.00M
Price to Earnings (P/E)24.0
Beta0.55
Next Earnings
Nov 05, 2025EPS Estimate
0.99Last Dividend Ex-Date
May 19, 2025Dividend Yield1.39%
Share Statistics
EPS (TTM)1.15
Shares Outstanding55,948,257
10 Day Avg. Volume229,269
30 Day Avg. Volume176,038
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)0.00
Price to Sales (P/S)0.00
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€103.20Price Target Upside21.41% Upside
Rating ConsensusHold
Number of Analyst Covering5
Bulls Say, Bears Say
Bulls Say
Financial PerformanceDiaSorin reported fourth-quarter results which slightly beat expectations on topline and EBITDA, indicating a strong start to the year.
Guidance And Future GrowthFY25 guidance of approximately 8% ex. COVID CER growth and around 34% EBITDA margins was reiterated, providing a conservative outlook that instills investor confidence.
Product GrowthManagement highlighted a combined year-over-year growth of around 25% for Verigene and LIAISON PLEX, suggesting robust growth in Molecular Diagnostics for FY25.
Bears Say
Molecular DiagnosticsThe headline of a lower Molecular Diagnostic fourth quarter into a strong respiratory season was unexpected, indicating potential challenges in this segment.
Quarterly PerformanceDiaSorin reported a fourth-quarter result that was approximately 2% below consensus on topline and EBITDA, though it still achieved FY24 guidance.
Slowing GrowthEuropean growth slowed to 4% CER, suggesting a normalization after previously strong growth driven by high market share tests.
DiaSorin S.p.A. News
DIA FAQ
What was DiaSorin S.p.A.’s price range in the past 12 months?
DiaSorin S.p.A. lowest stock price was €83.14 and its highest was €112.35 in the past 12 months.
What is DiaSorin S.p.A.’s market cap?
DiaSorin S.p.A.’s market cap is €4.67B.
When is DiaSorin S.p.A.’s upcoming earnings report date?
DiaSorin S.p.A.’s upcoming earnings report date is Nov 05, 2025 which is in 89 days.
How were DiaSorin S.p.A.’s earnings last quarter?
DiaSorin S.p.A. released its earnings results on Jul 31, 2025. The company reported €1.154 earnings per share for the quarter, beating the consensus estimate of €1.119 by €0.035.
Is DiaSorin S.p.A. overvalued?
According to Wall Street analysts DiaSorin S.p.A.’s price is currently Undervalued.
Does DiaSorin S.p.A. pay dividends?
DiaSorin S.p.A. pays a Annually dividend of €1.2 which represents an annual dividend yield of 1.39%. See more information on DiaSorin S.p.A. dividends here
What is DiaSorin S.p.A.’s EPS estimate?
DiaSorin S.p.A.’s EPS estimate is 0.99.
How many shares outstanding does DiaSorin S.p.A. have?
DiaSorin S.p.A. has 55,948,257 shares outstanding.
What happened to DiaSorin S.p.A.’s price movement after its last earnings report?
DiaSorin S.p.A. reported an EPS of €1.154 in its last earnings report, beating expectations of €1.119. Following the earnings report the stock price went down -2.768%.
Which hedge fund is a major shareholder of DiaSorin S.p.A.?
Currently, no hedge funds are holding shares in IT:DIA
Company Description
DiaSorin S.p.A.
DiaSorin S.p.A. develops, manufactures, and distributes immunodiagnostics and molecular diagnostics testing kits in Europe, Africa, North America, Central and South America, the Asia Pacific, and China. The company provides various immunodiagnostic LIAISON platforms, including LIAISON XS, LIAISON XL, and LIAISON XL LAS; and molecular diagnostics platform comprising of LIAISON MDX for use in the amplification of nucleic acids to diagnose viral infections through the identification of virus in patient's biological sample. It has partnership agreements with QIAGEN for diagnostic solution for Latent Tuberculosis detection; TTP for the development of molecular Point-of-Care solution; and MeMed for the launch of a test differentiating between viral and bacterial infections. The company was founded in 1968 and is headquartered in Saluggia, Italy.
DIA Stock 12 Month Forecast
Average Price Target
€103.20
▲(21.41% Upside)
Technical Analysis
Ownership Overview
12.49% Insiders
6.43%
Mutual Funds
― Other Institutional Investors
76.86% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---